SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted a matched, test-negative, case-control study to estimate duration of protection of the second and third/booster doses of mRNA COVID-19 vaccines against BA.1 and BA.2 infections in Qatar. BNT162b2 effectiveness was highest at 46.6% (95% CI: 33.4-57.2%) against symptomatic BA.1 and at 51.7% (95% CI: 43.2-58.9%) against symptomatic BA.2 infections in the first three months after the second dose, but declined to ~10% or below thereafter. Effectiveness rebounded to 59.9% (95% CI: 51.2-67.0%) and 43.7% (95% CI: 36.5-50.0%), respectively, in the first month after the booster dose, before declining again. Effectiveness against COVID-19 hospitalization and death was...
Objectives: To characterize the clinical severity of covid-19 associated with the alpha, delta, and...
BackgroundBrazil and Scotland have used mRNA boosters in their respective populations since Septembe...
Key messages and recommendations Thispopulation-based study documentsBNT162b2vaccine protection week...
Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and the emergence of the om...
The protection conferred by natural immunity, vaccination, and both against symptomatic severe acute...
BACKGROUND: Waning of vaccine protection against severe acute respiratory syndrome coronavirus 2 (SA...
Compared to BA.1, BA.2 was associated with lower RT-qPCR cycle threshold (Ct) value-3.53 fewer cycle...
During June-October 2022, the SARS-CoV-2 Omicron BA.5 sublineage accounted for most of the sequenced...
There is significant genetic distance between SARS-CoV-2 Omicron (B.1.1.529) variant BA.1 and BA.2 s...
In October of 2022, Qatar introduced COVID-19 bivalent vaccination for persons ≥ 12 years using the ...
BackgroundUnderstanding protection conferred by natural SARS-CoV-2 infection versus COVID-19 vaccina...
The future of the SARS-CoV-2 pandemic hinges on virus evolution and duration of immune protection of...
The SARS-CoV-2 Omicron variant (B.1.1.529 or BA.1) became predominant in the United States by late D...
BACKGROUND: Estimates of immunity and severity for the SARS-CoV-2 omicron subvariant BA.5 are import...
The BA.4 and BA.5 subvariants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B....
Objectives: To characterize the clinical severity of covid-19 associated with the alpha, delta, and...
BackgroundBrazil and Scotland have used mRNA boosters in their respective populations since Septembe...
Key messages and recommendations Thispopulation-based study documentsBNT162b2vaccine protection week...
Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and the emergence of the om...
The protection conferred by natural immunity, vaccination, and both against symptomatic severe acute...
BACKGROUND: Waning of vaccine protection against severe acute respiratory syndrome coronavirus 2 (SA...
Compared to BA.1, BA.2 was associated with lower RT-qPCR cycle threshold (Ct) value-3.53 fewer cycle...
During June-October 2022, the SARS-CoV-2 Omicron BA.5 sublineage accounted for most of the sequenced...
There is significant genetic distance between SARS-CoV-2 Omicron (B.1.1.529) variant BA.1 and BA.2 s...
In October of 2022, Qatar introduced COVID-19 bivalent vaccination for persons ≥ 12 years using the ...
BackgroundUnderstanding protection conferred by natural SARS-CoV-2 infection versus COVID-19 vaccina...
The future of the SARS-CoV-2 pandemic hinges on virus evolution and duration of immune protection of...
The SARS-CoV-2 Omicron variant (B.1.1.529 or BA.1) became predominant in the United States by late D...
BACKGROUND: Estimates of immunity and severity for the SARS-CoV-2 omicron subvariant BA.5 are import...
The BA.4 and BA.5 subvariants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B....
Objectives: To characterize the clinical severity of covid-19 associated with the alpha, delta, and...
BackgroundBrazil and Scotland have used mRNA boosters in their respective populations since Septembe...
Key messages and recommendations Thispopulation-based study documentsBNT162b2vaccine protection week...